|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Eight fresh, primary and non cultured GBMs were used in order to study the gene expression signatures from its CD133 positive and negative populations isolated by FACS-sorting.
|
20735813 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.
|
20467331 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we report that miR-29b and miR-125a are downregulated in glioblastomas and also in CD133-positive cells.
|
20665731 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, flow cytometry characterization of A2B5(+)-derived spheres revealed three distinct populations of cells: A2B5(+)/CD133(+), A2B5(+)/CD133(-) and A2B5(-)/CD133(-), with striking proportion differences among GBM.
|
19243384 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we observed no significant effects on cell proliferation and migration in CD133 overexpressed U87MG human glioblastoma cells.
|
20800650 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that some PTEN-deficient GBM tumors produce a series of CD133(+) and CD133(-) self-renewing tumor-initiating cell types and provide evidence that these cell types constitute a lineage hierarchy.
|
20385361 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PKD2 was also expressed in CD133-positive glioblastoma stem cells and various glioblastoma cell lines in which the kinase was found to be constitutively active.
|
21727210 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
|
21220328 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we report miRNA expression profiles of glioblastoma stem cell-containing CD133(+) cell populations.
|
21857646 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings constitute conclusive evidence that the measurement of the mRNA expression of CD133 stem cell antigen actually impacts the survival of GBM patients.
|
21479688 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastomas (GBM) may contain a variable proportion of active cancer stem cells (CSCs) capable of self-renewal, of aggregating into CD133(+) neurospheres, and to develop intracranial tumors that phenocopy the original ones.
|
22174890 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two cell lines, GBM1 and GBM2, were established from CD133-positive cells sorted on an automagnetic cell separator from dispersed human glioblastoma cells.
|
21380601 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GSf lines are highly tumorigenic and invasive in vivo, express CD133, grow spherically in vitro, are multipotent and display a Proneural gene expression signature, thus recapitulating key functional and transcriptional aspects of human glioblastomas.
|
21294158 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 mRNA and CD133 protein could be detected in all relevant types of glioblastoma cell lines.
|
21901757 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NG2 was frequently co-expressed with nestin and vimentin but rarely with CD133 and the NG2 positive tumour cells harboured genetic aberrations typical for GBM.
|
21863242 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In our study, glioma stem cells (GSCs) expressing the surface marker CD133 from human glioblastoma cell line U251 were isolated using MACS column and were analyzed using immunofluorescence and flow cytometry (FCM).
|
21300033 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we characterize the expression and role of Bmi1 in primary minimally cultured human glioblastoma (GBM) patient isolates in CD133+ and CD133- sorted populations.
|
22265735 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
|
22431923 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice.
|
22098779 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that the cluster of differentiation (CD)166/activated leukocyte cell adhesion molecule (ALCAM) was highly expressed on CD133+ glioblastoma progenitor cells.
|
22166264 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we found that CD133 positive GSCs possess a unique miRNAs profile compared to CD133 negative glioblastoma cells. miR-125b, as one of neuronal miRNAs, is the most significantly down-regulated miRNAs and overexpression of miR-125b inhibits the proliferation of CD133 positive GSCs and reduces the expression of "stem" marker.
|
22999819 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GBM6 was derived from a glioblastoma close to the subventricular zone, whereas GBM9 was derived from a cortical glioblastoma and contained a high number of CD133(+) cells.
|
21989663 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also demonstrated that human glioblastoma cells previously cultured under high oxygen tension can lose part of their aggressiveness when orthotopically engrafted in SCID mice or lead to tumors with distinct phenotypes and no re-expression of AC133.
|
22134773 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
|
22748652 |
2012 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation and protein expression of MGMT in a homogenous group of GBM patients uniformly treated with radiotherapy and TMZ.
|
23245659 |
2012 |